4-(氯甲基)-四氢-2H-吡喃 | 863324-23-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氧烷类
• 中文名称: 4-(氯甲基)-四氢-2H-吡喃
• 英文名称: 4-(chloromethyl)tetrahydro-2H-pyran
• 英文别名: 4-(chloromethyl)oxane
• CAS: 863324-23-6
• 化学式: C₆H₁₁ClO
• mdl: MFCD16745652
• 分子量: 134.606
• InChiKey: DULFMEBLCDFSDB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  8
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

安全信息

• 危险类别：
  3,8
• 危险性防范说明：
  P210,P233,P240,P241,P242,P243,P260,P264,P280,P301+P330+P331,P303+P361+P353,P304+P340,P305+P351+P338,P310,P363,P370+P378,P403+P235,P405,P501
• 危险品运输编号：
  2924
• 危险性描述：
  H225,H314
• 包装等级：
  III

反应信息

• 作为反应物：
  描述：

  4-(氯甲基)-四氢-2H-吡喃 在 正丁基锂 、 potassium carbonate 作用下， 以 四氢呋喃 为溶剂， 反应 21.0h， 生成
  参考文献：
  名称：

  CN117209539

  摘要：

  公开号：

文献信息

• Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors
  申请人：ASTRAZENECA AB

  公开号：US09522894B2

  公开（公告）日：2016-12-20

  The present disclosure relates to certain (2S)—N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamide compounds (including pharmaceutically acceptable salts thereof), that inhibit dipeptidyl peptidase 1 (DPP1) activity, to their utility in treating and/or preventing clinical conditions including respiratory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), to their use in therapy, to pharmaceutical compositions containing them and to processes for preparing such compounds.

  本公开涉及特定（2S）-N-[(1S)-1-氰基-2-苯乙基]-1,4-噁唑烷-2-甲酰胺化合物（包括其药用盐），其抑制二肽基肽酶1（DPP1）活性，以及它们在治疗和/或预防包括哮喘和慢性阻塞性肺病（COPD）在内的临床疾病中的用途，它们在治疗中的应用，含有它们的药物组合物以及制备这类化合物的方法。
• SULFIDE ALKYL COMPOUNDS FOR HBV TREATMENT
  申请人：NOVIRA THERAPEUTICS, INC.

  公开号：US20160151375A1

  公开（公告）日：2016-06-02

  The present invention includes a method of inhibiting, suppressing or preventing HBV infection in an individual in need thereof, comprising administering to the individual a therapeutically effective amount of at least one compound of the invention.

  本发明涉及一种抑制、抑制或预防HBV感染的方法，包括向需要的个体施用本发明中至少一种化合物的治疗有效量。
• [EN] 3,4-DISUBSTITUTED PYRAZOLES AS CYCLIN DEPENDENT KINASES (CDK) OR AURORA KINASE OR GLYCOGEN SYNTHASE 3 (GSK-3) INHIBITORS<br/>[FR] PYRAZOLES 3,4-DISUBSTITUTES SERVANT D'INHIBITEURS DE KINASES CYCLINES DEPENDANTES (CDK), OU DE KINASES AURORA OU DE GLYCOGENE SYNTASES 3 (GSK-3)
  申请人：ASTEX TECHNOLOGY LTD

  公开号：WO2006003440A1

  公开（公告）日：2006-01-12

  The invention provides compounds of the formula (I); or salts or solvates or N-oxides thereof; wherein: Rq is selected from groups (a), (b) and (c); the asterisk denoting the point of attachment to the pyrazole ring; X is N or CR5; X' is NR4', O, S or S(O); A is a bond or -(CH2)m-(B)n-; B is C=O, NRg(C=O) or O(C=O) wherein Rg is hydrogen or C1-4 hydrocarbyl optionally substituted by hydroxy or C1-4 alkoxy; m is 0, 1 or 2; n is 0 or 1; R0 is hydrogen or, together with NRg when present, forms a group -(CH2)p- wherein p is 2 to 4; and R1 to R6b are as defined in the description. Compounds of the formula (I) have activity as inhibitors of CDK, aurora and GSK-3 kinases are useful in treating or preventing diseases such as cancers that are mediated by the said kinases.

  本发明提供式(I)的化合物；或其盐、溶剂化物或N-氧化物；其中：Rq选自基团(a)、(b)和(c)；星号表示与吡唑环的连接点；X为N或CR5；X'为NR4'、O、S或S(O)；A为键或-(CH2)m-(B)n-；B为C=O、NRg(C=O)或O(C=O)，其中Rg为氢或C1-4烃基，可选择性地被羟基或C1-4烷氧基取代；m为0、1或2；n为0或1；R0为氢，或与存在的NRg一起形成基团-( )p-，其中p为2至4；R1至R6b如说明书中所定义。式(I)的化合物作为CDK、aurora和GSK-3激酶的抑制剂，对于治疗或预防由所述激酶介导的疾病，如癌症，具有用途。
• CERTAIN (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES AS DIPEPTIDYL PEPTIDASE 1 INHIBITORS
  申请人：ASTRAZENECA AB

  公开号：US20150210655A1

  公开（公告）日：2015-07-30

  The present disclosure relates to certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamide compounds (including pharmaceutically acceptable salts thereof), that inhibit dipeptidyl peptidase 1 (DPP1) activity, to their utility in treating and/or preventing clinical conditions including respiratory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), to their use in therapy, to pharmaceutical compositions containing them and to processes for preparing such compounds.

  本公开涉及某些（2S）-N-[(1S)-1-氰基-2-苯乙基]-1,4-噁唑烷-2-羧酰胺化合物（包括其药用盐），其抑制二肽基肽酶1（DPP1）活性，用于治疗和/或预防包括哮喘和慢性阻塞性肺病（COPD）在内的临床疾病，以及它们在治疗中的用途，含有它们的药物组合物以及制备这类化合物的方法。
• 3,4-Disubstituted Pyrazoles as Cyclin Dependent Kinases (Cdk) or Aurora Kinase or Glycogen Synthase 3 (Gsk-3) Inhibitors
  申请人：Gill Liam Adrian

  公开号：US20080004270A1

  公开（公告）日：2008-01-03

  The invention provides compounds of the formula (I); or salts or solvates or N-oxides thereof; wherein: R q is selected from groups (a), (b) and (c); the asterisk denoting the point of attachment to the pyrazole ring; X is N or CR 5 ; X″ is NR 4 ; O, S or S(O); A is a bond or —(CH 2 ) m —(B) n —; B is C═O, NR g (C═O) or O(C═O) wherein R g is hydrogen or C 1-4 hydrocarbyl optionally substituted by hydroxy or C 1-4 alkoxy; m is 0, 1 or 2; n is 0 or 1; R 0 is hydrogen or, together with NR g when present, forms a group —(CH 2 ) p — wherein p is 2 to 4; and R 1 to R 6b are as defined in the description. Compounds of the formula (I) have activity as inhibitors of CDK, aurora and GSK-3 kinases are useful in treating or preventing diseases such as cancers that are mediated by the said kinases.

  本发明提供了式（I）的化合物；或其盐、溶剂或N-氧化物；其中：Rq选择自组（a）、（b）和（c）；星号表示与吡唑环的连接点；X为N或CR5；X″为NR4；O、S或S（O）；A为键或—（CH2）m—（B）n—；B为C═O、NRg（C═O）或O（C═O），其中Rg为氢或C1-4烃基，可选地被羟基或C1-4烷氧基取代；m为0、1或2；n为0或1；R0为氢或与NRg一起，形成—（ ）p—基团，其中p为2至4；R1至R6如描述中所定义。式（I）的化合物具有作为CDK、极光激酶和GSK-3激酶抑制剂的活性，可用于治疗或预防由该激酶介导的癌症等疾病。